<DOC>
	<DOCNO>NCT02465736</DOCNO>
	<brief_summary>The primary objective compare docetaxel plus cisplatin ( DP ) versus vinorelbine plus cisplatin ( NP ) neoadjuvant chemoradiotherapy , term overall survival toxicity patient Stage IIB III squamous cell esophageal carcinoma .</brief_summary>
	<brief_title>Study Docetaxel Vinorelbine Plus Cisplatin Neoadjuvant Chemoradiotherapy Esophageal Cancer</brief_title>
	<detailed_description>Esophageal cancer ( EC ) eighth common cancer world , 456,000 new case 400,000 death occur annually worldwide . Every year China , matter new case death account half world . Besides , 90 % Chinese patient esophageal squamous cell carcinoma ( ESCC ) . Preoperative chemoradiotherapy ( CRT ) follow surgery hopefully improve survival ESCC . The CROSS trial demonstrate preoperative chemoradiotherapy significantly increase overall survival patient EC compare surgery alone . The therapeutic effect also find 84 ESCC case enrol trial . Previously , investigator perform phase III , randomize clinical trial ( NCT01216527 ) compare overall survival stage IIB-III ESCC patient treat without neoadjuvant CRT , vinorelbine plus cisplatin use chemotherapy regime . The enrollment complete 2014 . The outcome hopefully prove survival benefit neoadjuvant CRT ESCC . However , investigator also observe patient suffer toxic response neoadjuvant therapy , myelosuppression ( 45.2 % ) , pulmonary toxicity ( 42.9 % ) , esophagitis ( 59.5 % ) . The toxicity cause CRT decrease patient compliance ; moreover increase perioperative complication death , may totally offset survival benefit . Therefore , important improve chemoradiotherapy effect reduce toxicity , achieve good survival ESCC patient . Docetaxel draw increase attention high effective rate low toxicity . Several Phase II clinical trial retrospective study suggest docetaxel show good survival benefit monotherapy combined-therapy EC patient . Therefore , investigator intend conduct phase III , randomize clinical trial explore whether docetaxel plus cisplatin would effective therapy low toxicity . The investigator carry phase III clinical trial compare effect toxicity docetaxel plus cisplatin vinorelbine plus cisplatin neoadjuvant chemoradiotherapy esophageal squamous cell carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Histologic diagnosis squamous cell thoracic esophageal carcinoma Stage T14aN13M0 T4aN0M0 , accord 7th edition Union International Cancer Control ( UICC ) stag system . 2 . Patients must receive prior anticancer therapy . 3 . More 6 month expect survival 4 . Age range 18 70 year 5 . Absolute white blood cell count ≥4.0×109/L , neutrophil ≥1.5×109/L , platelet ≥100.0×109/L , hemoglobin ≥90g/L , normal function liver kidney . 6. WHO performance status ( PS ) 01 7 . Signed informed consent document file 1 . Patients receive prior anticancer therapy 2 . Patients advance inoperable metastatic esophageal carcinoma 3 . Patients concomitant hemorrhagic disease 4 . Patients uncontrollable status tolerate surgery 5 . Pregnant breast feed 6 . Patients sign informed consent document psychological quality , family social factor 7 . Patients concomitant peripheral neuropathy , whose CTC status 2 even 8 . Have prior malignancy esophageal carcinoma , carcinoma situ cervix , nonmelanoma skin cancer cure early stage prostate cancer 9 . Have history diabetes 10 year poorly control blood sugar level 10. patient serious cardiac , respiratory , hepatic , renal , hematologic , immunological disease cachexy , tolerate chemoradiotherapy surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>